Goldman Sachs Reaffirms Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
In a report released on January 31, Davinthra Thillainathan from Goldman Sachs maintained a Buy rating on Resmed Inc CHESS Depositary Interests ...
Hosted on MSN1d
ResMed Inc. Reports Changes in CDI and Security Issuances
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ) just unveiled an update. ResMed Inc. has ...
UBS upgrades Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) to a Buy
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – Research Report) received a Buy rating and price target from ...
ResMed's SWOT analysis: sleep tech giant faces GLP-1 drug challenge
ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...
ResMed targets 59-60% gross margins and expanded global reach for AirSense 11
CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...
ResMed: Digital Health Drives Q2 Growth
ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...
fnarena6d
ResMed: Another Positive Quarterly Surprise?
UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...